clinical trial · NCT07445087
A Study of Takhzyro in Teenagers and Adults With Hereditary Angioedema (HAE) in South Korea
Takeda·—·not yet recruiting·n = 35
Hereditary Angioedema (HAE)No intervention
brief summary
Takhzyro is an approved treatment for hereditary angioedema (HAE) in South Korea. HAE is a rare condition which causes sudden swelling under the skin and inside the body, like in the belly, throat, or genitals. The main aim of this study is to check how safe Takhzyro is in teenagers and adults with HAE in everyday medical care in South Korea. Another aim is to see how well Takhzyro works in everyday medical care. The treatment of participants and any check-ups will be determined by the treating doctors according to their normal practice. Participants may visit the study clinic several times during the study.
started
Oct 1, 2026
primary completion
Feb 29, 2032
completion
Feb 29, 2032
last updated
Jun 18, 2026
official title
A Post Marketing Surveillance Study (Usage Results Study) for Takhzyro in South Korea
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol